Incyte (1INCY) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1INCY Analyst Ratings

Moderate Buy

11 Buy

10 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1INCY Stock 12 Month Forecast

Average Price Target

€112.19

▼(>-0.01% Downside)

Based on 21 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is €112.19 with a high forecast of €132.96 and a low forecast of €89.21. The average price target represents a >-0.01% change from the last price of €112.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"63":"€63","98":"€98","133":"€133","80.5":"€80.5","115.5":"€115.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132.9604725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€132.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.19245302631579,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€112.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.212188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€89.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[63,80.5,98,115.5,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.4,106.59695942307692,108.79391884615386,110.99087826923078,113.1878376923077,115.38479711538463,117.58175653846155,119.77871596153847,121.97567538461539,124.17263480769232,126.36959423076924,128.56655365384617,130.7635130769231,{"y":132.9604725,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.4,104.99941946356276,105.59883892712551,106.19825839068827,106.79767785425102,107.39709731781377,107.99651678137653,108.59593624493927,109.19535570850202,109.79477517206477,110.39419463562753,110.99361409919028,111.59303356275304,{"y":112.19245302631579,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.4,103.23170676923077,102.06341353846155,100.89512030769231,99.72682707692309,98.55853384615385,97.39024061538461,96.22194738461539,95.05365415384615,93.88536092307692,92.7170676923077,91.54877446153846,90.38048123076923,{"y":89.212188,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€132.96

Average Price Target€112.19

Lowest Price Target€89.21

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

€128.67

Buy

14.68%

Upside

Reiterated

08/27/26

Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150

John Newman

Canaccord Genuity

€130.39

Buy

16.21%

Upside

Initiated

08/21/26

Incyte initiated with a Buy at CanaccordIncyte initiated with a Buy at Canaccord

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/19/26

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

Allison Bratzel

Piper Sandler

€94.36→€111.52

Buy

-0.61%

Downside

Reiterated

08/17/26

Incyte price target raised to $130 from $110 at Piper SandlerIncyte price target raised to $130 from $110 at Piper Sandler

Evan Seigerman

BMO Capital

€111.52

Hold

-0.61%

Downside

Reiterated

08/17/26

BMO Capital Remains a Hold on Incyte (INCY)

Jeffrey Walch

Bernstein

€84.92→€89.21

Hold

-20.49%

Downside

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: HealthStream (NASDAQ: HSTM), Incyte (NASDAQ: INCY) and Hyperion DeFi (NASDAQ: HYPD)

Derek Archila

Wells Fargo

€99.51

Hold

-11.31%

Downside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biodesix (NASDAQ: BDSX), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Andrew Berens

Leerink Partners

€112.37→€132.96

Buy

18.50%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Salim Syed

Mizuho Securities

€103.79→€117.52

Buy

4.74%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Jessica Fye

J.P. Morgan

€94.36→€102.94

Hold

-8.26%

Downside

Assigned

07/30/26

Incyte price target raised to $120 from $110 at JPMorganIncyte price target raised to $120 from $110 at JPMorgan

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Incyte (NASDAQ: INCY)

Salveen Richter

Goldman Sachs

€94.36→€101.22

Hold

-9.78%

Downside

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)

Judah Frommer

Morgan Stanley

€89.21→€102.08

Hold

-9.02%

Downside

Reiterated

07/29/26

Incyte price target raised to $119 from $104 at Morgan StanleyIncyte price target raised to $119 from $104 at Morgan Stanley

Etzer Darout

Barclays

€114.95→€119.24

Buy

6.27%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)

Michael Schmidt

Guggenheim

€116.66→€128.67

Buy

14.68%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

€128.67

Buy

14.68%

Upside

Reiterated

08/27/26

Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150

John Newman

Canaccord Genuity

€130.39

Buy

16.21%

Upside

Initiated

08/21/26

Incyte initiated with a Buy at CanaccordIncyte initiated with a Buy at Canaccord

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/19/26

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

Allison Bratzel

Piper Sandler

€94.36→€111.52

Buy

-0.61%

Downside

Reiterated

08/17/26

Incyte price target raised to $130 from $110 at Piper SandlerIncyte price target raised to $130 from $110 at Piper Sandler

Evan Seigerman

BMO Capital

€111.52

Hold

-0.61%

Downside

Reiterated

08/17/26

BMO Capital Remains a Hold on Incyte (INCY)

Jeffrey Walch

Bernstein

€84.92→€89.21

Hold

-20.49%

Downside

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: HealthStream (NASDAQ: HSTM), Incyte (NASDAQ: INCY) and Hyperion DeFi (NASDAQ: HYPD)

Derek Archila

Wells Fargo

€99.51

Hold

-11.31%

Downside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biodesix (NASDAQ: BDSX), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Andrew Berens

Leerink Partners

€112.37→€132.96

Buy

18.50%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Salim Syed

Mizuho Securities

€103.79→€117.52

Buy

4.74%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Jessica Fye

J.P. Morgan

€94.36→€102.94

Hold

-8.26%

Downside

Assigned

07/30/26

Incyte price target raised to $120 from $110 at JPMorganIncyte price target raised to $120 from $110 at JPMorgan

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Incyte (NASDAQ: INCY)

Salveen Richter

Goldman Sachs

€94.36→€101.22

Hold

-9.78%

Downside

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)

Judah Frommer

Morgan Stanley

€89.21→€102.08

Hold

-9.02%

Downside

Reiterated

07/29/26

Incyte price target raised to $119 from $104 at Morgan StanleyIncyte price target raised to $119 from $104 at Morgan Stanley

Etzer Darout

Barclays

€114.95→€119.24

Buy

6.27%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)

Michael Schmidt

Guggenheim

€116.66→€128.67

Buy

14.68%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months

Michael SchmidtGuggenheim

Success Rate

19/26 ratings generated profit

Average Return

+8.98%

Copying Michael Schmidt's trades and holding each position for 3 Months would result in 73.08% of your transactions generating a profit, with an average return of +8.98% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

18/18 ratings generated profit

Average Return

+39.21%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +39.21% per trade.

2 Years

Tazeen AhmadBank of America Securities

Success Rate

18/18 ratings generated profit

Average Return

+57.46%

Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1INCY Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1INCY has received 40 Buy Ratings, 40 Hold Ratings, and 2 Sell Ratings. 1INCY average Analyst price target in the past 3 months is 112.19.

Each month's total comprises the sum of three months' worth of ratings.

1INCY Financial Forecast

1INCY Earnings Forecast

Next quarter’s earnings estimate for 1INCY is -€2.42 with a range of -€3.52 to €1.69. The previous quarter’s EPS was €2.65. 1INCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1INCY has Performed in-line its overall industry.

1INCY Sales Forecast

Next quarter’s sales forecast for 1INCY is €1.26B with a range of €1.24B to €1.29B. The previous quarter’s sales results were €1.43B. 1INCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1INCY has Performed in-line its overall industry.

1INCY Stock Forecast FAQ

What is IT:1INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 112.19.

What is IT:1INCY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IT:1INCY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Incyte Corp a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 10 hold ratings and 0 sell ratings.

What is Incyte Corp’s share price target?

The average share price target for Incyte Corp is 112.19. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €132.96 ,and the lowest forecast is €89.21. The average share price target represents >-0.01% Decrease from the current price of €112.2.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Incyte Corp?

To buy shares of IT:1INCY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Incyte (1INCY) Stock Forecast & Price Target

1INCY Analyst Ratings

1INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

1INCY Analyst Recommendation Trends

1INCY Financial Forecast

1INCY Earnings Forecast

1INCY Sales Forecast

1INCY Stock Forecast FAQ

Detailed List of Analyst Forecasts